Pharmacotherapy considerations in transgender individuals living with human immunodeficiency virus

被引：6

作者：

Badowski, Melissa E. ^{[1
]}

Britt, Nicholas ^{[2
]}

Huesgen, Emily C. ^{[3
]}

Lewis, Michelle M. ^{[4
]}

Miller, Misty M. ^{[5
]}

Nowak, Kathleen ^{[6
]}

Sherman, Elizabeth ^{[7
]}

Smith, Renata O. ^{[1
]}

机构：

[1] Univ Illinois, Coll Pharm, 833 S Wood,Room 164,MC886, Chicago, IL 60612 USA

[2] Univ Kansas, Sch Pharm, Kansas City, KS USA

[3] Indiana Univ Hlth, Indianapolis, IN USA

[4] Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK USA

[5] Univ Oklahoma, Hlth Sci Ctr, Coll Pharm, Oklahoma City, OK 73190 USA

[6] Epocrates, Asheville, NC USA

[7] Nova Southeastern Univ, Coll Pharm, Ft Lauderdale, FL 33314 USA

来源：

PHARMACOTHERAPY | 2021年 / 41卷 / 03期

关键词：

antiretroviral therapy; hormone therapy; human immunodeficiency virus; transgender;

D O I：

10.1002/phar.2499

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Pharmacotherapy considerations are often a concern for transgender individuals who are living with human immunodeficiency virus (HIV) due to concerns for drug-drug interactions between their hormone and antiretroviral therapies. Many of the first-line therapies offered to patients for the management of HIV have reduced concerns for safety, resistance, and drug-drug interactions. In this review, we highlight common medications and important considerations for caring for transgender people living with HIV.

引用

页码：299 / 314

页数：16

共 74 条

[1] Comparative pharmacokinetics and pharmacodynamics after subcutaneous and intramuscular administration of medroxyprogesterone acetate (25 mg) and estradiol cypionate (5 mg) [J].

Alfredo Sierra-Ramirez, Jose ;

Lara-Ricalde, Roger ;

Lujan, Miguel ;

Velazquez-Ramirez, Norma ;

Godinez-Victoria, Marycarmen ;

Araceli Hernadez-Munguia, Ivonne ;

Padilla, Agustin ;

Garza-Flores, Josue .

CONTRACEPTION, 2011, 84 (06) :565-570

[2]

[Anonymous], INT STAT CLASSIFICAT

[3]

[Anonymous], 2018, Gallup News

[4]

[Anonymous], 2016, Guidelines for the primary and gender-affirming care of transgender and gender nonbinary people

[5]

[Anonymous], 2019, HIV and transgender people

[6]

[Anonymous], Accelerating Acceptance 2017: A Harris Poll Survey of Americans' Acceptance of LGBTQ People

[7]

[Anonymous], 2018, GLAAD MEDIA REFERENC

[8]

[Anonymous], 2016, REPORT 2015 US TRANS

[9] The pharmacokinetics and efficacy of different estrogens are not equivalent [J].

Ansbacher, R .

AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2001, 184 (03) :255-263

[10]

ASSCHEMAN H, 1988, CLIN ENDOCRINOL, V28, P583, DOI 10.1111/j.1365-2265.1988.tb03849.x

← 1 2 3 4 5 6 7 8 →